European CHMP recommends licence extension of tezacaftor / ivacaftor (Symkevi)

The CHMP has recommended the approval of a new 50/75-mg strength for Symkevi tablets and an extension to the existing cystic fibrosis indication to allow use in children from 6 years of age.

European Medicines Agency